Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances

David Warwick, José M. Arandes-Renú, Giorgio Pajardi, Jörg Witthaut & Lawrence C. Hurst

To cite this article: David Warwick, José M. Arandes-Renú, Giorgio Pajardi, Jörg Witthaut & Lawrence C. Hurst (2016) Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances, Journal of Plastic Surgery and Hand Surgery, 50:5, 251-261, DOI: 10.3109/2000656X.2016.1159568

To link to this article: http://dx.doi.org/10.3109/2000656X.2016.1159568

© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group

Published online: 06 Apr 2016.

Submit your article to this journal

Article views: 617

View related articles

View Crossmark data
Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances

David Warwicka, José M. Arandes-Renúb, Giorgio Pajardic, Jörg Witthautd and Lawrence C. Hursted

aThe Hand Clinic, University Hospital Southampton, Hampshire, UK; bServicio de Cirugía Ortopédica y Traumatología, Unidad de Mano, Hospital Clinic, Barcelona, Spain; cDepartment of Hand Surgery, San Giuseppe MultiMedica University Hospital, Milan and Università degli Studi di, Milano, Italy; dHand Surgery, Schön Klinik Vogtareuth, Vogtareuth, Germany; eDepartment of Orthopaedics, Stony Brook School of Medicine, Stony Brook, NY, USA

ABSTRACT

Objective: This study aims to provide a comprehensive review of the role of Collagenase Clostridium histolyticum (CCH). Methods: This review is based on a literature review and practical experience. Results: This review provides practical management strategies for using collagenase by sharing clinical experiences over the past few years; logistical aspects of in-clinic treatment, lessons learned, and novel approaches to correct traditionally hard-to-treat contractures are discussed. In addition a brief, yet comprehensive overview is provided on the pathophysiology of the disease, the mechanism of collagenase action and results of clinical studies. Conclusion: CCH has an evolving role as one of the tools available for treating Dupuytren’s disease.

Background

Dupuytren’s disease

Dupuytren’s disease (DD) is a progressive fibroproliferative disorder that affects the palmar fascia, whereby early nodular tissue develops into a collagen cord. As the cord thickens and shortens over time, flexion deformity of the affected joints and web spaces ensues [1–3]. Impaired hand function is the usual presenting complaint, as affected individuals have difficulty performing daily activities secondary to the joint contracture [4–6]. Many are also embarrassed by the visible deformity [5].

DD is relatively common across Europe, in particular in people of Northern European origin [7,8]. It is more common in men [9], and the incidence increases with advancing age [10,11]. Additional risk factors include ethnicity [12], diabetes [13–15], exposure to anti-epileptics [16,17], alcohol consumption and cigarette smoking [18,19], and history of hand trauma and vibratory work [20–23]. Among the genetic predispositions, a mitochondrial rRNA mutation [24], changes in human leukocyte antigen (HLA) class II alleles [25], and alterations in the Wnt signalling pathway [26] are included. There is no cure for DD, and corrective surgery has been the mainstay of treatment for Dupuytren’s contracture (DC) since the clinical features of the disease were first described more than 200 years ago.

Collagenase Clostridium histolyticum (CCH) is the first non-surgical, pharmacologic treatment for DC with a palpable cord approved for use in the US and Europe. Clinical trials [27–29] and post-marketing surveillance [30] have demonstrated the efficacy and safety of CCH treatment for correcting DC. However, treating DC enzymatically is not a new concept. Early investigations began already in the 1960s, and in 1971 the use of a combination of digestive enzymes during open surgery was referred to as an “enzymic fasciotomy” [31] (Figure 1).

In this review, we aim to briefly describe the pathophysiology of DD and provide practical management strategies for the use of CCH in patients with DC by summarising the clinical experiences over the past few years [29].

Pathophysiology of Dupuytren’s disease

During the past 30 years, great advances have been made in our understanding of the pathophysiology of DD. The important role of myofibroblasts was first described in 1972 [32]. Later the presence of non-muscle myosin, actin, and fibronectin in DD tissue was identified [33] and the importance of myofibroblasts and their regulation by calcium adenosinetriphosphatase in the contractile process was described [34,35]. The importance of integrin and fibronectin in the contractile process was also described [36]. In more recent years profiling of haematopoietic and mesenchymal stem cells in tissues biopsied from DD patients and from those undergoing surgery for carpal tunnel syndrome (controls) was performed to identify the potential source of DD cells. RNA expression of stem cell markers was higher in DD patients and distinct stem cell populations were identified in DD tissues including...
cords, nodules, perinodular fat, and skin, supporting the hypothesis that DD may result from mesenchymal progenitor cell expansion [37].

Three histologic stages characterise the disease process [38]:

- **Proliferative stage**: there is an increased production of fibroblasts that cluster to form nodules.
- **Involutional stage**: fibroblasts differentiate into myofibroblasts, and growth factors, particularly transforming growth factor-β, facilitate their rapid and extensive proliferation [39]. A combination of chemical and tensile forces confers contractile properties onto the tissue and results in the deposition of extracellular matrix (ECM) proteins, especially collagen [40].
- **Residual stage**: cellular activity ceases, leaving the inelastic collagen cord to span joints of the hand, shorten, and cause fixed flexion contracture (FFC) of the affected joint [41].

Of the ECM proteins assembled and deposited by myofibroblasts, collagen types I, III, IV, and V are the most prevalent [42]. In normal palmar fascia, type I collagen predominates, whereas in DD affected tissue the predominant form is type III collagen [43–46], which is also a prominent contributor to the pathogenesis of DD [41]. Compared with normal fascia, there is a 10%–20% increase in type III collagen in nodules and a 30%–40% increase in cords.

Due to its triple helix structure, cross-linking, and glycosylation, collagen is a stable protein. Matrix metalloproteinases (MMPs) and cathepsins (L and H) are the only mammalian enzymes that possess collagenase activity. Relevant for DD is the collagenase activity of MMP, which is controlled through synthesis, activation of latent MMPs, inactivation of other active enzymes, and an acidic pH environment [47,48]. Collagen accumulation in DD is the net result of deposition and degradation, the balance of which is determined by the local environment.

**Collagenase Clostridium histolyticum (CCH)**

The discovery of collagenase started in the early 1930s when the digestive activity of filtrates from cultured *Clostridium histolyticum* on small fragments of equine Achilles tendon was described [49,50]. The enzyme responsible for the effect was later named collagenase, as its digestive activity turned out to be exclusive to collagen [51]. In 1996, CCH, which is composed of two distinct collagenases isolated from *Clostridium histolyticum*, was introduced as a potential candidate for pharmacotherapy for patients with DD for the first time [52].

As a new molecular entity, CCH comprises a fixed-ratio mixture of two purified collagenolytic enzymes, clostridial type I collagenase (AUX-I) and clostridial type II collagenase (AUX-II) [53]. Clostridial type I and type II collagenases are calcium- and zinc-dependent MMPs. The enzymes differ in terms of structure, affinity, cleavage site, and catalytic efficiency (Table 1). By virtue of these differences in attributes, when the two collagenases are combined, the enzymatic activity is improved over that observed with either class acting alone [53].

In the first study exploring the therapeutic potential of CCH experiments were performed on DD cords excised from patients undergoing fasciectomy. The goals were three-fold: (1) to determine the range of CCH doses required for clinical utility; (2) to define the minimal effective dose needed to cause complete cord rupture; and (3) to quantify the force...
required during the finger extension procedure to facilitate cord rupture. The study demonstrated that a minimal effective dose of 300 units was required to rupture a cord using normal extension force, and that the effect increased relative to dose [52].

Later, the effect of CCH on primary fibroblasts obtained from different anatomic sites in tissue biopsied from patients with DD or carpal tunnel syndrome was investigated [54]. At the cellular level, CCH inhibited the spreading, attachment, and proliferation of fibroblasts in a dose- and time-dependent manner. At the transcriptional level, CCH also showed dose-dependent inhibition of several ECM components, cytokines, and growth factors [54]. When CCH was removed, the cellular processes of DD tissues recovered in nodules, cords, and skin, but not fat. This recovery may be due to the presence of myofibroblasts [32] or stem-like cells associated with DD [37].

**Clinical efficacy of CCH**

The clinical efficacy of CCH has been evaluated in at least 13 studies, including one phase I, three Phase II, and nine Phase III clinical trials conducted in the US, Europe, and Australia.

**CORD I and CORD II**

In the pre-licensing Phase III clinical trials, CORD I (Collagenase Option for Reduction of Dupuytren) and CORD II, as well as in a single centre study of similar design, CCH, was efficacious compared to placebo in reducing contractures to ≤5° of normal finger extension [28,29,55].

**Efficacy and safety in patient sub-groups**

In a retrospective study of data from three randomised placebo-controlled trials [28,29,55], the efficacy and safety of CCH were evaluated in sub-groups of patients previously shown to be at increased risk for surgical complications [56]. Gender, age, or diabetes did not affect the complication rate. The frequency or nature of AEs was also similar to other studies.

**Efficacy after previous surgery**

Recurrence after surgery for DC is frequent and may require retreatment. Retrospective data from 12 clinical trials were pooled to evaluate the relative efficacy of CCH in patients who had undergone previous surgery for DC [57]. Overall, these findings suggest that previous surgery for DC does not affect its efficacy or safety, and that CCH is a viable option among patients with recurring DC.

**Recurrence**

CORDLESS (CORD Long-Term Evaluation of Safety Study) is a follow-up study of patients from the CORD and JOINT studies [58]. Recurrence in a joint that had achieved clinical success with CCH was defined as either a ≥20° worsening in contracture with a palpable cord, or a medical/surgical intervention to correct a new or worsening contracture. At 3 years, of the 1080 joints that had been treated, 35% returned (27% MP joint, 56% PIP joints) and, of these, an intervention was performed in 8%. By 5 years, 40% of metacarpophalangeal cords and 66% of proximal interphalangeal cords recurred.

**Clinical practice**

**US chart review**

In a retrospective review of charts from patients treated with CCH in 2010, an assessment of the effectiveness of CCH in clinical practice, rather than a research protocol, was performed. Overall, the effectiveness of CCH was comparable to the efficacy in clinical trials; in the “real-world” study, fewer injections were needed to gain an improvement than in the research studies. This is likely due to the widespread use of local anaesthetic during the extension procedure, which may have allowed the use of greater and more prolonged force to facilitate cord disruption compared to the clinical trials where local anaesthetic was not allowed [30].
One-year US post-marketing safety study
During the first 3 years after the FDA approved CCH for DC (February 2010–February 2013), ~49,000 injections were given, and 1732 AEs were reported for 864 patients [59]. The most commonly reported AEs were skin tears (13%), peripheral oedema (9.5%), and contusion (9.7%). There were 26 tendon ruptures (0.05%). The nature and frequency of AEs during this period were comparable to those observed in the clinical trials; no new safety signals were detected in this analysis and no safety-related changes were made to the product label.

Practical guidance from experienced surgeons
Establishing a CCH practice
Candidates for CCH treatment are patients with a palpable cord and an identifiable functional problem rather than an indication strictly based on the degree of the contracture.

Symptoms are, however, most likely to manifest after a contracture of ≥30°. There is no indication for prophylactic treatment with CCH, or for nodules alone. Nor is the use of CCH advised for patients with deficient or severely damaged skin.

Educating patients regarding alternatives, treatment procedure, reasonable expectations, and potential risks is important.

Injection procedure
The instructions in the package insert and other educational material for dosing, reconstitution, and administration should be followed strictly. After CCH is reconstituted, the solution should preferably be drawn into a 0.5 ml syringe (with 0.01 ml intervals), which allows accurate divided administration. A fixed needle, rather than a removable needle, is advised to avoid expensive wastage in the event of detachment. In theory, a local anaesthetic before the injection may interfere with proper placement of the injection and mask inadvertent penetration of a digital nerve. Spray analgesia (e.g. ethyl chloride) reduces needle pain. Cold spray should not be sprayed onto the needle as this can constrict flow. Palpation is of utmost importance to create a mental image of the underlying pathoanatomy before an injection. Also, be aware that not all flexed fingers have Dupuytren’s cords – other pathologies such as a neurological contracture, post-traumatic PIP contracture, or locked trigger finger may co-exist.

Great care should be taken not to advance the needle with the plunger, such that the injection is too deep and is deposited dorsal to the cord. Using both hands to control the needle during the injection is often helpful. Digital cords can be injected parallel to the palm rather than in the perpendicular plane to reduce the chance of tendon penetration. Injections may be given by inserting the needle through the skin only once; however, placement of the needle in separate spots along the cord allows for more accurate yet widespread deposition of aliquots and aids in the management of complex cords. If only one joint is to be treated, but both MP and PIP joints are contracted, then CCH should be administered across the MP cord first. In many patients, a PIP contracture will correct due to the dynamism of the cord [60].

Data from a recently published trial suggest that two affected joints can be effectively and safely treated with concurrent CCH injections into the same hand in patients with multiple contractures [61]. Another study suggests that a larger dose can be used, off label, and with due consent and caution, for multiple cords [62].

Finger extension procedure
According to the initial studies, the finger extension procedure should be performed the day after the injection, but recent studies show that a delay of up to 7 days after injection gives equivalent results [63,64]. Both the EMA and FDA have approved manipulation up to 72 hours later.

A four-step finger extension procedure is recommended to maximise disruption of the cord and minimise skin tears (Figure 2). A local anaesthetic is administered as a metacarpal or wrist block before the extension procedure. Cord disruption is almost always successful after a single manipulation; however, some surgeons recommend repeating the extension procedure two or three times, even if the first procedure breaks the cord. If there are adjacent cords such as natatory connections to the adjacent finger, these should be manipulated as well; rupture is common. Secondary ruptures can occur, contributing to a better outcome. Massaging the cord, eliciting the sensation of “bubble wrap”, can very effectively improve the contracture.

Immediately after the manipulation, a soft compressive bandage can be applied, allowing patients to move the hand while protecting the skin from accidental snagging. The skin can be vulnerable for a few days after the injection, especially if there is a blood blister or skin tear. Some surgeons forgo a bandage, splinting the finger immediately after the extension procedure.

Splinting
There is no evidence about whether splinting confers benefit, and the extent to which type of splint may be best has not been studied in detail. Moreover, it has been shown that patient adherence with their use is low [65,66]. Use of splints will depend upon the surgeon’s and hand therapist’s opinion. Some recommend static night extension splinting for 3 months after CCH treatment. Starting the night splinting with a little flexion and gradually straightening it over several nights is generally less painful. Splints that can be adjusted by the patient are commercially available. For PIP joints that are still contracted after CCH lysed the cord, daytime use of a PIP reverse knuckle bender splint is appropriate. Occasionally, surgical addition of a Digit Widget™ might be considered for severely stiffened PIP joints, although we are not aware of any reports.

Finger flexion and extension exercises
Patients should be advised to use the hand as normally as possible immediately after the finger extension procedure,
but avoid lifting heavy objects for 1–2 weeks. Follow-up by a qualified hand therapist may be necessary for some patients. Detailed instructions for daily hand and finger exercises can be found at: http://www.dupuytrens.stonybrook.edu/patient_exercise.cfm.

Frequency and purpose of follow-up visits

The frequency and nature of follow-up varies depending on the treating surgeon and the patient’s outcome, progress, and complications. If a skin tear occurs, the patient must be reassured that this is within the normal response after CCH injection. It will heal uneventfully in 2–4 weeks. At the 1-month follow-up visit, the results are checked and evaluated for the need for a second injection. If the first injection does not fully correct the contracture, or if there is more than one cord, then a further injection can be considered.

Patient satisfaction

Patient satisfaction depends on how successful the treatment is and on the patient’s expectations before the treatment. The patients may still be satisfied, even if there is some residual contracture [67]. It is important to inform the patient about the likely risk of recurrence in due course. A well informed patient with realistic expectations is more likely to be satisfied.

Recurrence

There is no broadly accepted definition of recurrence. Surgery in a field previously treated with CCH is generally not more challenging than primary surgery [68]. The use of CCH on patients with recurrence after surgery has been studied with good results and high patient satisfaction [57]. CCH works well in cords where the contracture is secondary to a recurrent visible and palpable cord, the joint is not stiff and there is healed skin over the cord. If there is insufficient skin between the proximal flexion crease and PIP flexion crease of the finger or diffuse involvement of the skin, surgical excision of the cord and skin grafting is probably more appropriate.

Safety concerns

Allergic reactions

Allergic reactions are extremely rare after treatment with CCH. One anaphylactic reaction was reported in a post-marketing clinical study of CCH for Dupuytren’s contracture in a patient who had previous exposure to CCH for the treatment of Dupuytren’s contracture, demonstrating that severe reactions including anaphylaxis can occur, and an anaphylactic reaction set must be available and the doctor must be familiar with its use. An immune response to CCH can manifest as axillary pain and/or lymphadenopathy, and the patient should be informed about the risk of such reactions. After treatment the patient should be observed for 30 minutes before leaving the clinic in order to monitor for any appearance of allergic reactions.

Oedema

Local swelling and some ecchymosis is common and to be expected when a bioactive drug is injected into the hand.
The swelling typically resolves within 24–48 hours after the injection. Patients should be advised to elevate their hand and to take prophylactic analgesics. Ecchymosis is usually mild; in more severe cases, the condition resolves within 10–14 days. Also blood blisters are relatively common after CCH injection and should be attended to and monitored, but are of little cause for concern.

**Skin tears**

In clinical practice, small skin tears occur in ~13% of cases [59] and are treated with standard wound care. The tears close rapidly and heal in 10–21 days and the quality of the regenerated skin is usually excellent. In rare cases, application of a graft has been necessary. It is thought that CCH spreading into the dermal-epidermal interval weakens the skin, and the tear develops during the extension procedure.

**Artery and nerve injury**

We are not aware of any instances of artery or nerve injury after CCH injection. No instances of artery or nerve injury occurred during CCH clinical trials [28,29,55], and there were no reports of artery or nerve injury in the 3-year post-marketing safety study [59].

**Tendon rupture**

In the CORD I study, two patients experienced tendon ruptures [28] and in the CORD II study one patient had a flexion pulley rupture after treatment with CCH [29]. During the first 36 months after FDA approval, there were 26 reports of tendon rupture after ~49 000 injections of CCH were given to patients with DC in the US (0.05%) [59]. During that time and since, several tactics have been developed to avoid or minimise the risk for tendon rupture. First, CCH should not be injected near the PIP flexion crease of the little finger; however, if this is unavoidable, the needle should be oriented so that it is parallel to the palm and facing outward rather than toward the tendon. Second, occasionally in some patients who have had previous surgery, the flexor sheaths rupture; consequently the flexor tendons are “bow-strung”, such that the displaced tendons can cause flexion contractures, and the tendon itself can look like a Dupuytren’s cord. Third, it is important to remember that the distance from the skin to the flexor sheath in the palm is ~7 mm and at the PIP joint, this distance is only 4 mm. When assessing how deep to insert the needle, remember that the needle bevel measures 11°/4 mm. Fourth, a tendon is more likely to rupture only if an entire dose of CCH has been injected into it.

**Other serious injuries**

Two cases of finger fractures have been reported. These events occurred as complications of the finger extension procedure.

**Treatment advances in previously challenging cases**

**Efficacy of CCH in patients with comorbid conditions**

**Diabetes**

Diabetes patients generally have increased surgical risk and CCH might for this reason be the preferred treatment option in this patient group. However, in clinical trials the efficacy and safety of CCH treatment was comparable between patients with or without diabetes [56]. All patient medications and special diets should continue without modification.

**Patients taking anticoagulants**

The use of anticoagulants is restricted in those taking anticoagulants. The CCH label advises that the drug should be used with caution with the exception of up to 150 mg daily of acetylsalicylic acid. One possibility for patients taking anticoagulants is to transition them to heparin 4–7 days before the injection. Clotting rates can be checked on the injection day, and the transition back to their anticoagulant medication can begin the day after, if the finger extension procedure does not result in a skin tear.

The use of CCH in patients with a clotting disorder or anticoagulant drug should be individualised and fully discussed with the patient. There are significant risks in stopping anticoagulants in some patients. Some doctors may be content to use CCH with the same practice as they would with surgery which might allow its use if the INR is below 2.5 [69].

**Efficacy of CCH in hard-to-treat cords**

**PIP joints**

PIP contractures are more difficult than MP contractures to treat using corrective surgery or percutaneous needle fasciotomy (PNF) [70–72], and rates of recurrence are generally high [73]. Anatomic differences leave the PIP joint more susceptible to blood blisters, tendon rupture, and higher recurrence rates with CCH. When both the MP and PIP joints on the same finger are contracted by the same cord, CCH treatment of the MP joint sometimes corrects both contractures. The portion of the PIP contracture caused by the cord is predictably corrected by the finger extension procedure. In some patients with severe PIP contractures (>40°), there may be several cords, some of which may not be palpable. In these cases, the use of ultrasound to guide the injection(s) may be useful. PIP contractures can also be caused by non-DD-related factors such as a contracted volar plate, contracted collateral ligaments of the PIP joint, arthritic changes in the joint, and attenuation of the extensor mechanism of the PIP joint. Thus, the likelihood of complete correction of a PIP contracture is not as good as that for complete correction of an MP contracture.

**Central cord**

A central cord develops from the pretendinous band, which is a retention ligament extending from the palm into the fibrofatty tissues of the finger. This cord can cause an MP
contracture or a combined MP and PIP contracture (Figure 3). The typical result after CCH treatment of a combined MP and PIP contracture is full correction of the MP and partial but sufficient correction of the PIP cord.

Crow-foot cord
A crow-foot cord is a combination of a central cord and two natatory cords extending into the adjacent fingers on either side, causing MP contractures in three fingers (Figure 4). Usually, all three contractures can be corrected with a single dose.

“Y” cord and Super “Y” cord
The “Y” cord is a combination of a central cord and a natatory cord and adjacent finger, and the Super “Y” cord causes MP contractures in two fingers separated by an uninvolved finger with no contracture (Figure 5). Usually, these contractures can be corrected with a divided, single dose treatment.

Abductor digiti minimi cords
The abductor digiti minimi cord starts at the insertion of the site of the abductor digiti minimi into the ulnar base of the fifth finger proximal phalanx. The cord extends distally to the ulnar base of the middle phalanx. This cord typically causes PIP contractures and does not involve the MP joint unless there is an associated central cord. An isolated abductor digiti minimi cord that has not been previously treated usually responds well to CCH treatment. Aliquots should be injected into the proximal half of the cord, as this area has the most separation from the underlying flexor tendon sheath.

Commissural and radial thumb cord
Thumb contractures (Figure 6) are caused by commissural cords and radial thumb cords, often occurring together. They typically close the first web space and adduct the thumb. In a small percentage of patients, these contractures can be severe and disabling, limiting the use of the thumb by making normal pinch and grip nearly impossible [74,75]. CCH is successfully used for treating thumb cords [76]. Occasionally, thumb cords can be thick enough to require a second injection of CCH 30 days later.

Other complex cords
Various complex cord combinations exist that require careful analysis to determine junction points of the component cords.
and the areas that are most separated from the underlying flexor tendons. Such complex cords can also be successfully treated with a single dose of CCH.

**Technical advances**

**Delayed finger extension procedure**

The finger extension procedure is typically performed the day after the CCH injection. In the recent MULTICORD study the extension procedure was delayed until 48 or 72 hours without any difference in the efficacy or safety profile [63,64].

**Multiple injections**

In case additional treatment is required the next injections are given after 30 days. However, recent studies revealed that treatment of multiple joints using two concurrent injections resulted in comparable improvement to those seen in previous studies [61,62]. Multiple concurrent injections for effective treatment of patients with multiple affected joints would benefit the patient and enhance the cost-effectiveness of the drug, which is otherwise currently a challenge. For these reasons, the FDA in the US and the EMA in Europe have approved the use of two concurrent injections.

Dividing a single dose of CCH into aliquots is an alternative successful treatment of complex combined cords like the “Y” cord. A single dose can also be divided to treat two separate cords that are not connected. However, success will be determined by the thickness of the cords, since the volume splitting will only work if they are very thin with a small cross-sectional diameter.
Conclusion

Overall, the skills required to perform CCH injection and finger manipulation procedures are not difficult to acquire. A detailed knowledge of hand anatomy and the means to manage any complications is essential. CCH injection is a simple, efficacious, and well tolerated alternative to surgery. Patient satisfaction is generally high, especially when patients are well informed about the technique and have reasonable expectations regarding outcomes and are informed about the risk of recurrence. Recurrence rates after CCH are higher than surgery. Nevertheless, recurrence may occur in suitable cases with a second injection. If surgery is required after treatment with CCH, it is not more complex than a primary procedure.

Recent research suggests that an increased dose, multiple injections, and delayed manipulation appear to be safe and effective. These advances will increase the utility and improve the cost effectiveness of CCH.

Acknowledgements

This work was sponsored by Pfizer Inc. and Swedish Orphan Biovitrum AB. We thank Linda A. Goldstein, PhD, of UBC Scientific Solutions, who provided medical writing services funded by Pfizer Inc. and Kristina Lindsten, PhD, medical writer at Swedish Orphan Biovitrum AB for participation in manuscript revision. The authors acknowledge the support of Robert Gerber and Piotr Szczypa of Pfizer Inc., Jim Tursi of Auxilium Pharmaceuticals, and Hans Olivecrona of Swedish Orphan Biovitrum. Funding for Open Access reproduction of this paper has been provided by Swedish Orphan Biovitrum. The figures are provided by Dr L. Hurst who maintains copyright.

Disclosure statement

DW has received honoraria and travel expenses for advisory board work with Pfizer Ltd. and Swedish Orphan Biovitrum. JMAR, and GP have received honoraria and travel expenses for advisory board work with Pfizer Ltd. JW has served as a speaker and participated in advisory boards for Pfizer Ltd. LCH has received research support from Auxilium Pharmaceuticals, Biospecific Technologies Corp (BTC), the US Food and Drug Administration, and National Institutes of Health; LCH also serves as a consultant to Auxilium Pharmaceuticals and the State University of New York at Stony Brook and receives royalties from BTC. DW, GP, JW, and LCH were study investigators as part of the CCH clinical trial programme.

References

1. Black EM, Blazar PE. Dupuytren disease: an evolving understanding of an age-old disease. J Am Acad Orthop Surg 2011;19:746–57.
2. Rayan GM. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007;89:189–98.
3. Shaw RB Jr., Chong AK, Zhang A; et al. Dupuytren’s disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007;120: 44e–54e.
4. Bayat A, McGrouther DA. Management of Dupuytren’s disease-clear advice for an elusive condition. Ann R Coll Surg Engl 2006;88:3–8.
5. Hobby JL, Dias JJ. A review of hand surgery provision in England. J Hand Surg Br 2006;31:230–5.
6. Pratt AL, Byrne G. The lived experience of Dupuytren’s disease of the hand. J Clin Nurs 2009;18:1793–802.
7. Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren’s disease incidence and prevalence rates in relation to etiology. Hand (NY) 2009;4:256–69.
8. Hart MG, Hooper G. Clinical associations of Dupuytren’s disease. Postgrad Med J 2005;81:425–8.
9. Wilbrand S, Ekborn A, Gerdin B. The sex ratio and rate of reoperation for Dupuytren’s contracture in men and women. J Hand Surg Br 1999;24:456–9.
10. Gudmundsson KG, Arngrimsson R, Sigfusson N; et al. Epidemiology of Dupuytren’s disease: clinical, serological, and social assessment. The Reykjavik study. J Clin Epidemiol 2000;53:291–6.
11. Höët F, Bokho J, Decoster E; et al. [Dupuytren’s disease. Review of 326 surgically treated patients]. Ann Chir Main 1988;7:251–5.
12. Saboeiro AP, PORKorny JJ, Shehadi SI; et al. Racial distribution of Dupuytren’s disease in Department of Veterans Affairs patients. Plast Reconstr Surg 2000;106:71–5.
13. Arkkila PE, Kantola IM, Viikari JS. Dupuytren’s disease: association with chronic diabetic complications. J Rheumatol 1997;24:153–9.
14. Aydeniz A, Gursoy S, Gunez E. Which musculoskeletal complications are most frequently seen in type 2 diabetes mellitus? J Int Med Res 2008;36:505–11.
15. Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 1984;66:322–5.
16. Arafa M, Noble J, Royle SG, et al. Dupuytren's and epilepsy revisited. J Hand Surg Br 1992;17:221–4.
17. Bickley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry 1976;39:498–503.
18. Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997;79:206–10.
19. Godtfredsen NS, Lucht H, Prescott E, et al. A prospective study linked both alcohol and tobacco to Dupuytren's disease. J Clin Epidemiol 2004;57:858–63.
20. Bovenzi M. Hand-arm vibration syndrome: diagnostic aspects, dose-response relationship and exposure limits. Med Lav 1994;85:463–73.
21. Cocco PL, Frau P, Rapallo M, Casula D. Occupational exposure to vibration and Dupuytren's disease: a case-controlled study. Med Lav 1987;78:386–92.
22. Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med 1996;29:521–32.
23. Thomas PR, Clarke D. Vibration white finger and Dupuytren's contracture: are they related? Occup Med (Lond) 1992;42:155–5.
24. Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. J Hand Surg Br 2005;29:113–41.
25. McCarty S, Syed F, Bayat A. Role of the HLA system in the pathogenesis of Dupuytren's disease. Hand (NY) 2010;5:241–50.
26. Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and extracellular matrix of the Dupuytren's disease 'myofibroblast': an immunofluorescence study of a nonmuscle cell type. J Hand Surg Am 2010;35:2027–38.
27. Witthaut J, Jones G, Skrepnik N, et al. Efficacy and safety of collagenase clostridium histolyticum for Dupuytren's disease. Plast Reconstr Surg 2005;115:134–41.
28. Hueston JT. Enzymic fasciotomy. Hand 1971;3:38–40.
29. Peimer CA, Skodny P, Mackowiak JI. Collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am 2013;38:2–11.
30. Syed F, Thomas AN, Singh S, et al. In vitro study of novel collagenase clostridium histolyticum for Dupuytren's disease. J Hand Surg Am 2010;35:2027–38.
31. Thomas PR, Clarke D. Vibration white finger and Dupuytren's contracture: are they related? Occup Med (Lond) 1992;42:155–5.
32. Verhayden JR. Early outcomes of a sequential series of 144 patient increased dose, multicord technique. J Hand Surg 2015;40:133–40.
33. Tomasko TJ, Galpin D, Colema S, Hall S, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010;35:2027–38.
34. Peimer CA, Skodny P, Mackowiak JI. Collagenase clostridium histolyticum for Dupuytren's disease. Plast Reconstr Surg 2005;115:134–41.
35. Syed F, Thomas AN, Singh S, et al. In vitro study of novel collagenase Clostridium histolyticum (AA4500) in the treatment of advanced Dupuytren's disease [http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm182012.html], 2009.
36. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271–90.
37. Badalamente MA, Hurst LC, Finchum MJ, et al. Delayed manipulation of Dupuytren's contracture. J Bone Joint Surg Br 1997;79:206–10.
38. Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlara study. J Bone Joint Surg Am 1980;62:425–32.
39. Menzel EJ, Piza H, Zielinski C, et al. Collagen types and antcollagen-antibodies in Dupuytren's disease. Hand 1979;11:243–8.
40. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995;3:527–30.
41. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271–90.
42. Badalamente MA, Hurst LC, Finchum MJ, et al. Delayed manipulation of Dupuytren's contracture. J Bone Joint Surg Br 1997;79:206–10.
43. Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlara study. J Bone Joint Surg Am 1980;62:425–32.
44. Menzel EJ, Piza H, Zielinski C, et al. Collagen types and antcollagen-antibodies in Dupuytren's disease. Hand 1979;11:243–8.
45. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995;3:527–30.
46. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271–90.
47. Badalamente MA, Hurst LC, Finchum MJ, et al. Delayed manipulation of Dupuytren's contracture. J Bone Joint Surg Br 1997;79:206–10.
48. Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlara study. J Bone Joint Surg Am 1980;62:425–32.
49. Menzel EJ, Piza H, Zielinski C, et al. Collagen types and antcollagen-antibodies in Dupuytren's disease. Hand 1979;11:243–8.
50. Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995;3:527–30.
51. Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271–90.
66. Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review. BMC Musculoskelet Disord 2008;9:104.

67. Warwick D, Amer M, Pajardi G, et al. Collagenase Clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg 2015;40E:142–32.

68. Hay DC, Louie DL, Earp BE, et al. Surgical findings in the treatment of Dupuytren's disease after initial treatment with clostridial collagenase. J Hand Surg 2014;39E:463–5.

69. Edmunds I, Avakian Z. Hand surgery on anticoagulated patients: a prospective study of 121 operations. Hand Surg 2010;15:109–13.

70. Au-Yong IT, Wildin CJ, Dias JJ, Page RE. A review of common practice in Dupuytren surgery. Tech Hand up Extrem Surg 2005;9:178–87.

71. Engstrand C, Boren L, Liedberg GM. Evaluation of activity limitation and digital extension in Dupuytren's contracture three months after fasciectomy and hand therapy interventions. J Hand Ther 2009;22:221–6.

72. Draviaraj KP, Chakrabarti I. Functional outcome after surgery for Dupuytren's contracture: a prospective study. J Hand Surg Am 2004;29:804–8.

73. Crean SM, Gerber RA, Le Graverand MP, et al. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies. J Hand Surg Eur 2011;36:396–407.

74. Figus A, Britto JA, Ragoowansi RH, Elliot D. A clinical analysis of Dupuytren's disease of the thumb. J Hand Surg Eur 2008;33:272–9.

75. Milner RH. Dupuytren's disease affecting the thumb and first web of the hand. J Hand Surg Br 2003;28:33–6.

76. Bendon CL, Giele HP. Collagenase for Dupuytren's disease of the thumb. J Bone Joint Surg Br 2012;94:1390–2.